WallStSmart
MBRX

Moleculin Biotech Inc

NASDAQ: MBRX · HEALTHCARE · BIOTECHNOLOGY

$2.34
-4.38% today

Updated 2026-06-05

Market cap
$14.09M
P/E ratio
P/S ratio
EPS (TTM)
$-16.16
Dividend yield
52W range
$2 – $24
Volume
0.2M

Moleculin Biotech Inc (MBRX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20152016201720182019202020212022202320242025
Operating cash flow$-423509.00$-3.76M$-7.32M$-12.20M$-17.20M$-17.77M$-18.95M$-27.64M$-24.10M$-23.86M$-22.73M
Capital expenditures$21000.00$21470.00$28000.00$417000.00$52000.00$376000.00$19000.00$67000.00$124000.00$13000.00$0.00
Depreciation
Stock-based comp$411474.00$707000.00$1.14M$1.54M$1.68M$2.37M$2.27M$1.98M$1.73M$1.66M
Free cash flow$-444509.00$-3.79M$-7.35M$-12.62M$-17.25M$-18.15M$-18.97M$-27.71M$-24.23M$-23.88M$-22.73M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00$104000.00
Share repurchases
Debt repayment
Net change in cash$4.98M$2.71M$-580000.00$3.60M$4.40M

Frequently asked questions

How much free cash flow does MBRX generate?

MBRX produced $-22.73M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is MBRX's balance sheet healthy?

MBRX holds $8.88M in cash and equivalents against — in long-term debt, on $15.01M of shareholder equity. That debt is best read against the cash flow the business throws off each year.